argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone329-310-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$44.74 million
Profitability
Miscellaneous
Employees73
OptionableOptionable
argenx (NASDAQ:ARGX) Frequently Asked Questions
What is argenx's stock symbol?
argenx trades on the NASDAQ under the ticker symbol "ARGX."
When is argenx's next earnings date?
What price target have analysts set for ARGX?
11 equities research analysts have issued 12 month target prices for argenx's stock. Their forecasts range from $110.00 to $161.00. On average, they expect argenx's stock price to reach $142.00 in the next year. This suggests a possible upside of 39.2% from the stock's current price. View Analyst Price Targets for argenx.
What is the consensus analysts' recommendation for argenx?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx.
What are Wall Street analysts saying about argenx stock?
Here are some recent quotes from research analysts about argenx stock:
- 1. According to Zacks Investment Research, "argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. " (1/3/2019)
- 2. Stifel Nicolaus analysts commented, "We continue to remain positive on the stock at these levels and reiterate our Buy rating. Key Points The AML development landscape is crowded but ARGX-110 stands alone as the only program targeting CD70. Given the poor outcomes in the elderly and high relapse rates in AML, there are many broad and targeted treatments (i.e., specific mutations, immunotherapies) currently in development. KOLs we spoke with indicated there is no silver bullet" when treating the disease and there certainly seems room for new treatments." (10/16/2018)
Has argenx been receiving favorable news coverage?
Media coverage about ARGX stock has been trending positive on Monday, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. argenx earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Are investors shorting argenx?
argenx saw a decline in short interest in the month of December. As of December 14th, there was short interest totalling 621,136 shares, a decline of 26.7% from the November 30th total of 847,917 shares. Based on an average daily volume of 289,696 shares, the short-interest ratio is presently 2.1 days. Currently, 1.7% of the company's shares are short sold. View argenx's Current Options Chain.
Who are some of argenx's key competitors?
Some companies that are related to argenx include Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN) and Spark Therapeutics (ONCE).
Who are argenx's key executives?
argenx's management team includes the folowing people:
- Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 47)
- Mr. Eric Castaldi, Chief Financial Officer (Age 55)
- Prof. Hans de Haard, Chief Scientific Officer (Age 59)
- Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 55)
- Dr. Torsten Dreier, Chief Devel. Officer (Age 55)
When did argenx IPO?
(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are argenx's major shareholders?
argenx's stock is owned by a number of of retail and institutional investors. Top institutional investors include Dorsey Wright & Associates (0.15%).
Which major investors are selling argenx stock?
ARGX stock was sold by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates.
How do I buy shares of argenx?
Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is argenx's stock price today?
One share of ARGX stock can currently be purchased for approximately $102.04.
How big of a company is argenx?
argenx has a market capitalization of $3.28 billion and generates $44.74 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. argenx employs 73 workers across the globe.
What is argenx's official website?
How can I contact argenx?
argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]
MarketBeat Community Rating for argenx (NASDAQ ARGX)
MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
